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Credit Designation
The Medical University of South Carolina designates this enduring material for a maximum of
1 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the
extent of their participation in the activity.
Accreditation Information
The Medical University of South Carolina is accredited by the Accreditation Council for Continuing Medical Education
(ACCME) to provide continuing medical education for physicians.
Learning Outcome Objectives
At the completion of this CME enduring material, you should be able to:
(1) Distinguish between existing/newly available versus investigational aerosolized antibiotics for treating chronic CF
respiratory infections
(2) Apply therapeutic strategies involving intermittent and continuous antibiotic therapy to suppress chronic airway
infections using aerosolized antibiotics
(3) Recognize the importance of clinical outcomes in selecting aerosolized antibiotics for treating pulmonary infections in
patients with CF
Successful Completion
To access your CME certiﬁcate, you must complete the post-test with a score of 70% or higher and complete the evaluation.
To take the post-test for this article you will need to visit http://tinyurl.com/7nh9utt. Complete the registration form to
begin the testing process.
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